A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs LJPC 501 (Primary)
- Indications Hypotension
- Focus Registrational; Therapeutic Use
- Acronyms ATHOS-3
- Sponsors La Jolla Pharmaceutical Company
- 21 May 2017 Results from this trial published in a La Jolla Pharmaceutical Company media release.
- 12 May 2017 Results published in the New England Journal of Medicine.
- 27 Apr 2017 According to a La Jolla Pharmaceutical Company, the company expects New Drug Application submission in the second half of 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History